Education
About Us
Working with TipRanks
Follow Us
Orasure (OSUR)
:OSUR
Top Page
Orasure Technologies
(NASDAQ:OSUR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.00
▼(-1.32% Downside)
Orasure Technologies faces significant financial and valuation challenges, with declining revenues and profitability pressures being the most impactful factors. Technical analysis suggests a bearish trend, while the earnings call provided mixed signals, with some positive developments overshadowed by ongoing challenges.
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$216.49M
Dividend YieldN/A
Average Volume (3M)509.63K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth-49.35%
EPS Growth-285.61%
CountryUS
Employees501
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.26
Shares Outstanding73,136,986
10 Day Avg. Volume502,324
30 Day Avg. Volume509,632
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.65
Price to Sales (P/S)1.45
P/FCF Ratio11.40
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue0.08
Enterprise Value/Gross Profit0.07
Enterprise Value/Ebitda-0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Orasure Technologies Business Overview & Revenue Model
Company DescriptionOrasure Technologies, Inc. is a leading provider of oral fluid diagnostic products, specializing in the development, manufacture, and marketing of innovative medical devices and testing solutions. The company primarily operates in the healthcare sector, focusing on infectious disease testing, drug testing, and molecular diagnostics. Its core products include the OraQuick® rapid HIV test and the Intercept® oral fluid collection device, which are designed for ease of use and accuracy in various clinical and non-clinical settings.
How the Company Makes MoneyOrasure Technologies generates revenue primarily through the sale of its diagnostic products and testing services. Key revenue streams include the sale of rapid testing kits for infectious diseases and drug abuse, which are marketed to healthcare providers, laboratories, and government agencies. The company also earns income from licensing agreements and collaborations with other organizations to develop new testing technologies. Significant partnerships with public health organizations and collaborations with research institutions enhance its market reach and contribute to its earnings. Additionally, Orasure may benefit from government contracts and grants aimed at improving public health outcomes through innovative diagnostic solutions.
Orasure Technologies Earnings Call Summary
Earnings Call Date:Aug 05, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Neutral
The earnings call presented several highlights, including the successful launch of the HEMAcollect PROTEIN product and a strong cash position. However, these were offset by significant challenges, such as disruptions in international diagnostics and a decline in Sample Management revenue. The uncertainty in U.S. Diagnostics further balanced the positive developments.Q2-2025 Updates
Positive Updates
Successful Launch of HEMAcollect PROTEIN
In July, OTI launched HEMAcollect PROTEIN, which expands their Sample Management Solutions into a new sample type, blood. This product advances proteomic research by offering extended protein stabilization at room temperature and simplified workflows.
Strong Financial Position
OTI ended Q2 with $235 million in cash and cash equivalents and no debt, allowing them to continue investments in innovative products like Sherlock and Colli-Pee.
Renewal Agreement with GeneDx
OTI renewed their agreement with GeneDx, a long-standing customer, to support early diagnosis of rare pediatric diseases using their ORAcollect kits.
Negative Updates
Challenges in International Diagnostics
Despite year-over-year growth, international diagnostics faced disruptions due to USAID funding freezes, affecting the deployment pace of HIV tests.
Decline in Sample Management Revenue
Sample Management revenue decreased 22% year-over-year, primarily due to a large customer in the Consumer Genetics segment, impacting overall core revenue growth.
Uncertainty in U.S. Diagnostics Revenue
U.S. Diagnostics revenue declined 1% year-over-year, with uncertainty arising from potential cuts to public health program budgets and staffing reductions in key health agencies.
Company Guidance
In the OraSure Technologies Second Quarter 2025 Earnings Conference Call, the company reported total revenue of $31.2 million, with core revenue at $30.8 million, surpassing the midpoint of their guidance. The diagnostics segment grew by 3% year-over-year, while Sample Management revenue decreased by 22% due to a decline in orders from a major consumer genetics customer. Excluding this impact, Sample Management revenue would have shown positive growth. The international diagnostics business experienced year-over-year growth despite disruptions caused by USAID funding freezes, impacting the pace of HIV test deployments. The U.S. diagnostics revenue remained steady, declining just 1% year-over-year, influenced by potential public health program budget cuts. The company also highlighted the successful transition of manufacturing operations to Pennsylvania, completed ahead of schedule, and the launch of the HEMAcollect PROTEIN offering to support proteomic research. Looking ahead, OraSure guides for third-quarter revenue between $27 million and $30 million, with expectations of a slower pace of international orders and reduced revenue from the Together Take Me Home program.Orasure Technologies Financial Statement Overview
Summary
Orasure Technologies faces financial challenges with declining revenues and profitability, as indicated by a net loss and negative margins. Despite a strong balance sheet with low leverage, cash flow issues and operational inefficiencies are evident.Income Statement
Orasure Technologies has faced challenges in its income statement with declining revenues and profitability. The TTM (Trailing-Twelve-Months) shows a net loss with negative EBIT and EBITDA margins, indicating operational inefficiencies. Revenue growth has been erratic, with recent declines, suggesting volatility in sales performance.35
Negative
Balance Sheet
The balance sheet of Orasure Technologies is relatively strong, with a high equity ratio and low debt levels. The company's debt-to-equity ratio is low, implying low financial leverage and risk. However, despite strong equity, the return on equity is negative, highlighting the impact of ongoing losses.60
Neutral
Cash Flow
Cash flow analysis reveals a mixed picture. The company has generated positive operating cash flow in the TTM, but free cash flow has turned negative due to capital expenditures. The free cash flow to net income ratio indicates challenges in converting earnings to cash, suggesting operational inefficiencies.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.67M | 185.83M | 405.47M | 387.48M | 233.67M | 171.72M |
| Gross Profit | 43.19M | 79.39M | 179.42M | 147.64M | 117.60M | 101.87M |
| EBITDA | -45.78M | -5.13M | 64.35M | 10.29M | 9.00K | 3.44M |
| Net Income | -51.03M | -19.50M | 53.66M | -17.93M | -23.00M | -14.92M |
Balance Sheet | ||||||
| Total Assets | 445.04M | 479.66M | 482.85M | 444.71M | 460.99M | 454.47M |
| Cash, Cash Equivalents and Short-Term Investments | 234.58K | 267.76M | 290.41M | 110.85M | 153.04M | 209.40M |
| Total Debt | 14.13M | 14.60M | 13.50M | 12.55M | 12.27M | 6.13M |
| Total Liabilities | 64.31M | 69.32M | 52.17M | 81.08M | 80.46M | 55.90M |
| Stockholders Equity | 380.72M | 410.34M | 430.67M | 363.62M | 380.53M | 398.57M |
Cash Flow | ||||||
| Free Cash Flow | 12.16M | 23.58M | 131.28M | -111.11M | -83.50M | -23.12M |
| Operating Cash Flow | 12.76M | 27.37M | 141.58M | -47.20M | -35.38M | 5.81M |
| Investing Cash Flow | 273.00K | -39.03M | 66.15M | 21.09M | -5.50M | -14.03M |
| Financing Cash Flow | -7.59M | -4.18M | -3.02M | -3.83M | -2.82M | 92.48M |
Orasure Technologies Technical Analysis
Negative
3.04
Price Trends
3.15
Negative
3.09
Negative
3.20
Negative
Market Momentum
-0.07
Positive
38.14
Neutral
17.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Negative. The current price of 3.04 is below the 20-day moving average (MA) of 3.06, below the 50-day MA of 3.15, and below the 200-day MA of 3.20, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 38.14 is Neutral, neither overbought nor oversold. The STOCH value of 17.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 67 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orasure Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $281.41M | ― | -198.62% | ― | 33.94% | -6.91% | |
| ― | $93.15M | 10.70 | 26.60% | ― | 23.68% | 341.25% | |
| ― | $193.72M | 17.10 | 9.59% | 2.02% | -12.35% | ― | |
| ― | $196.04M | ― | -25.63% | ― | 19.57% | 61.81% | |
| ― | $276.64M | ― | -25.78% | ― | 34.29% | -49.21% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $216.49M | ― | -12.65% | ― | -49.35% | -285.61% |
* Healthcare Sector Average
OSUR
Orasure Technologies
2.89
-1.31
-31.19%
PDEX
Pro-Dex
28.87
-1.63
-5.34%
STXS
Stereotaxis
3.05
1.10
56.41%
UTMD
Utah Medical Products
59.23
-3.48
-5.55%
KRMD
REPRO-MED Systems
4.13
1.50
57.03%
SMTI
Sanara MedTech
30.50
-2.25
-6.87%
Orasure Technologies Corporate Events
OraSure’s Earnings Call: Mixed Outlook with Key Achievements
Aug 7, 2025
OraSure Technologies recently held its second-quarter earnings call, presenting a mixed outlook characterized by both achievements and challenges. While the company reported notable progress in revenue and innovation, it also faced significant hurdles in segments such as Sample Management and international diagnostics, primarily due to external factors. Despite advancements in strategic initiatives, immediate financial impacts remain a concern for the company.
OraSure Technologies Reports Q2 2025 Financial Results
Aug 6, 2025
OraSure Technologies, Inc., a leader in point-of-need and home diagnostic tests and sample management solutions, operates in the healthcare sector, focusing on improving access and quality of healthcare through innovative testing and sample management solutions.
Business Operations and StrategyFinancial Disclosures
OraSure Technologies Reports 43% Revenue Decline in Q2 2025
Negative
Aug 5, 2025
On August 5, 2025, OraSure Technologies announced its financial results for the quarter ended June 30, 2025. The company reported a decrease in total net revenues by 43% compared to the same period in 2024, with significant declines in molecular services and COVID-19 related revenues. Despite the revenue drop, OraSure is focused on expanding its product portfolio and commercial reach, with plans to launch new products and leverage its strong balance sheet for future growth.
The most recent analyst rating on (OSUR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.